CTLA4 and neoplasm: Treatment with anti‐PD‐1 and anti‐CTLA‐4 therapy led to the expansion of intratumoral CD69+CD103+CD8+ TRM cells, significantly increasing their cytotoxic capacity in TNBC patients and providing local immune protection against tumor rechallenge.243